Predictive Oncology (POAI) 10-Q 19 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 13, 2019
Document Information [Line Items]
Entity Registrant Name	Predictive Oncology Inc.
Entity Central Index Key	0001446159
Trading Symbol	poai
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		31,258,932
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and Cash Equivalents	$ 69,557	$ 162,152
Accounts Receivable	299,046	232,602
Notes Receivable (inclusive of $0 and $452,775 in advances to Helomics; net of $787,524 allowance for credit losses as of June 30, 2019)	250,000	497,276
Inventories	320,876	241,066
Prepaid Expense and other assets	154,523	318,431
Total Current Assets	1,094,002	1,451,527
Notes Receivable		1,112,524
Fixed Assets, net	1,769,813	180,453
Intangibles, net	4,591,872	964,495
Lease Right-of-Use Assets	1,005,525
Goodwill	23,790,290
Total Assets	32,251,502	3,708,999
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	3,538,832	445,689
Notes Payable –Net of Discounts of $573,155 and $1,032,814	3,808,751	1,634,914
Accrued Expenses	1,035,501	1,279,114
Derivative Liability	541,599	272,745
Deferred Revenue	29,706	23,065
Lease Liability – Net of Long-term Portion	501,427
Total Current Liabilities	9,455,816	3,655,527
Lease Liability	504,098
Total Liabilities	9,959,914	3,655,527
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 shares authorized, 30,974,761 and 14,091,748 outstanding	309,747	140,917
Additional paid-in capital	86,882,073	63,019,708
Accumulated Deficit	(64,936,025)	(63,107,945)
Total Stockholders' Equity	22,291,588	53,472
Total Liabilities and Stockholders' Equity	32,251,502	3,708,999
Series E Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series E Convertible Preferred Stock, $.01 par value, 350 shares authorized, 83.4 and 0 shares outstanding (Liquidation value $843,000)	1
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series E Convertible Preferred Stock, $.01 par value, 350 shares authorized, 83.4 and 0 shares outstanding (Liquidation value $843,000)	792	792
Series D Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series E Convertible Preferred Stock, $.01 par value, 350 shares authorized, 83.4 and 0 shares outstanding (Liquidation value $843,000)	$ 35,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Notes receivable	$ 250,000	$ 497,276
Reserve for bad debt	787,524	787,524
Discount of note payable	$ 573,155	$ 1,032,814
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	30,974,761	14,091,748
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01
Preferred stock, shares authorized (in shares)	350
Preferred stock, shares outstanding (in shares)	83.4
Preferred stock, liquidation value	$ 843,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	3,500,000	0
Helomics Holding [Member]
Notes receivable	$ 0	$ 452,775

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue	$ 286,151	$ 358,586	$ 541,392	$ 770,179
Cost of goods sold	118,390	108,970	192,106	226,314
Gross margin	167,761	249,616	349,286	543,865
General and administrative expense	3,310,368	729,528	4,808,314	1,945,670
Operations expense	1,271,258	378,906	1,737,824	666,496
Sales and marketing expense	685,029	554,084	1,239,245	1,104,623
Total operating loss	(5,098,894)	(1,412,902)	(7,436,097)	(3,172,924)
Gain on revaluation of cash advances to Helomics	1,222,244		1,222,244
Other income	(3,223)		50,209
Other Expense	819,283		1,389,059
Loss on equity method investment		960,508	439,637	960,508
Gain on revaluation of equity method investment	6,164,260		6,164,260
Net income/(loss)	1,465,104	(2,373,410)	(1,828,080)	(4,133,432)
Deemed dividend on Series E Convertible Preferred Stock	20,398		20,398
Net income/(loss) attributable to common shareholders per common shares – basic and diluted	$ 1,444,706	$ (2,373,410)	$ (1,848,478)	$ (4,133,432)
Gain/(loss) per common share - basic (in dollars per share)	$ 0.05	$ (0.20)	$ (0.08)	$ (0.36)
Gain/(loss) per common share – diluted (in dollars per share)	$ 0.02	$ (0.20)	$ (0.08)	$ (0.36)
Weighted average shares used in computation - basic (in shares)	29,609,373	11,878,490	22,747,544	11,632,221
Weighted average shares used in computation - diluted (in shares)	60,070,783	11,878,490	22,747,544	11,632,221

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Series E Warrants [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]	Series E Warrants [Member]Common Stock [Member]	Series E Warrants [Member]Additional Paid-in Capital [Member]	Series E Warrants [Member]Retained Earnings [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]	Re-priced Warrants [Member]Common Stock [Member]	Re-priced Warrants [Member]Additional Paid-in Capital [Member]	Re-priced Warrants [Member]Retained Earnings [Member]	Re-priced Warrants [Member]	Warrants Issued to CEO [Member]Preferred Stock [Member]	Warrants Issued to CEO [Member]Common Stock [Member]	Warrants Issued to CEO [Member]Additional Paid-in Capital [Member]	Warrants Issued to CEO [Member]Retained Earnings [Member]	Warrants Issued to CEO [Member]	Warrants Issued to Helomics' Investors [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Warrants Issued to Helomics' Investors [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Warrants Issued to Helomics' Investors [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Warrants Issued to Helomics' Investors [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Warrants Issued to Helomics' Investors [Member]Preferred Stock [Member]	Warrants Issued to Helomics' Investors [Member]Common Stock [Member]	Warrants Issued to Helomics' Investors [Member]Additional Paid-in Capital [Member]	Warrants Issued to Helomics' Investors [Member]Retained Earnings [Member]	Warrants Issued to Helomics' Investors [Member]	Warrants Held by Noteholders [Member]Preferred Stock [Member]	Warrants Held by Noteholders [Member]Common Stock [Member]	Warrants Held by Noteholders [Member]Additional Paid-in Capital [Member]	Warrants Held by Noteholders [Member]Retained Earnings [Member]	Warrants Held by Noteholders [Member]	Private Placement [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Private Placement [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Private Placement [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Private Placement [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Private Placement [Member]Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]	Over-Allotment Option [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]	Over-Allotment Option [Member]Common Stock [Member]	Over-Allotment Option [Member]Additional Paid-in Capital [Member]	Over-Allotment Option [Member]Retained Earnings [Member]	Over-Allotment Option [Member]	S-3 Public Offering [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	S-3 Public Offering [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	S-3 Public Offering [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	S-3 Public Offering [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	S-3 Public Offering [Member]Preferred Stock [Member]	S-3 Public Offering [Member]Common Stock [Member]	S-3 Public Offering [Member]Additional Paid-in Capital [Member]	S-3 Public Offering [Member]Retained Earnings [Member]	S-3 Public Offering [Member]	Helomics Acquisition, Inc. [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Helomics Acquisition, Inc. [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Helomics Acquisition, Inc. [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Helomics Acquisition, Inc. [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Helomics Acquisition, Inc. [Member]Preferred Stock [Member]	Helomics Acquisition, Inc. [Member]Common Stock [Member]	Helomics Acquisition, Inc. [Member]Additional Paid-in Capital [Member]	Helomics Acquisition, Inc. [Member]Retained Earnings [Member]	Helomics Acquisition, Inc. [Member]	Chief Executive Officer [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Chief Executive Officer [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Chief Executive Officer [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Chief Executive Officer [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Chief Executive Officer [Member]Preferred Stock [Member]	Chief Executive Officer [Member]Common Stock [Member]	Chief Executive Officer [Member]Additional Paid-in Capital [Member]	Chief Executive Officer [Member]Retained Earnings [Member]	Chief Executive Officer [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Preferred Stock [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Common Stock [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Additional Paid-in Capital [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]Retained Earnings [Member]	Shares Issued Pursuant to Note Conversions Bridge Loan [Member]	Investment Banker [Member]Preferred Stock [Member]	Investment Banker [Member]Common Stock [Member]	Investment Banker [Member]Additional Paid-in Capital [Member]	Investment Banker [Member]Retained Earnings [Member]	Investment Banker [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2017																																																																																																					$ 7,271	$ 69,432	$ 57,380,256	$ (54,765,045)	$ 2,691,913
Balance (in shares) at Dec. 31, 2017																																																																																																	647,819	79,246				6,943,283
Warrant exercises						$ 888	$ 87,948		$ 88,836						$ 2,523	$ 249,810		$ 252,333
Warrant exercises (in shares)						88,836									252,333
Vesting Expense																																																																																																							460,368		460,368
Net income (loss)																																																																																																								(4,133,432)	(4,133,432)
Stock issued for Helomics acquisition																																																																						$ 11,000	$ 1,031,250		$ 1,042,250
Stock issued for Helomics acquisition (in shares)																																																																						1,100,000
Preferred conversion to common shares pursuant to private placement agreement																																										$ (6,479)	$ 5,897	$ 582																																																													(6,479)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																						(647,819)					589,747
Shares issued pursuant to S-3 public offering																																																				$ 2,153	$ 202,268	$ 1	$ 204,422																																															$ 29,000	2,726,087		2,755,087
Shares issued pursuant to S-3 public offering (in shares)																																																				215,247																																																		2,900,000
Balance at Jun. 30, 2018																																																																																																					792	$ 120,893	62,138,569	(58,898,476)	3,361,778
Balance (in shares) at Jun. 30, 2018																																																																																																		79,246				12,089,446
Balance at Mar. 31, 2018																																																																																																					792	$ 118,040	61,622,067	(56,525,066)	5,215,833
Balance (in shares) at Mar. 31, 2018																																																																																																		79,246				11,804,073
Warrant exercises						$ 330	$ 32,710		$ 33,040						$ 2,523	$ 249,810		$ 252,333
Warrant exercises (in shares)						33,040									252,333
Vesting Expense																																																																																																							233,982		233,982
Net income (loss)																																																																																																								(2,373,410)	(2,373,410)
Balance at Jun. 30, 2018																																																																																																					792	$ 120,893	62,138,569	(58,898,476)	3,361,778
Balance (in shares) at Jun. 30, 2018																																																																																																		79,246				12,089,446
Balance at Dec. 31, 2018																																																																																																					792	$ 140,917	63,019,708	(63,107,945)	53,472
Balance (in shares) at Dec. 31, 2018																																																																																																		79,246				14,091,748
Warrant exercises																																																																																													$ 5,786			$ 5,786
Warrant exercises (in shares)																																																																																													578,560
Vesting Expense																																																																																																							1,644,220		1,644,220
Net income (loss)																																																																																																								(1,828,080)	(1,828,080)
Shares issued pursuant to note conversions																																																																																								$ 5,586	$ 232,987		$ 238,573
Shares issued pursuant to note conversions (in shares)																																																																																								558,588
Issuance of warrants																					$ 341,608		$ 341,608							$ 6,261,591		$ 6,261,591			$ 117,241		$ 117,241
Stock issued for Helomics acquisition																																																																																																					35,000	$ 40,000	5,537,250		5,612,250
Stock issued for Helomics acquisition (in shares)																																																																																																			3,500,000			4,000,000
Value of shares to extinguish debt																																																																																																						$ 86,373	6,376,936		6,463,309
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)
Issuance of Series E Preferred shares																																										$ 1		$ 743,559		$ 743,560
Issuance of Series E Preferred shares (in shares)																																									84
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering																																																													$ 28,638	$ 2,401,071		$ 2,429,709															$ 781	$ 49,219		$ 50,000
Shares issued pursuant to S-3 public offering (in shares)																																																													2,863,750																		78,125
Shares issued in forbearance agreement																																																																																																						$ 1,666	156,683		158,349
Shares issued in forbearance agreement (in shares)																																																																																																						166,667
Balance at Jun. 30, 2019																																																																																																					35,793	$ 309,747	86,882,073	(64,936,025)	22,291,588
Balance (in shares) at Jun. 30, 2019																																																																																																		79,246	3,500,000	84		30,974,761
Balance at Mar. 31, 2019																																																																																																					792	$ 173,601	66,296,741	(66,401,129)	70,005
Balance (in shares) at Mar. 31, 2019																																																																																																		79,246				17,360,144
Warrant exercises																																																																																																						$ 5,786			5,786
Warrant exercises (in shares)																																																																																																						578,560
Vesting Expense																																																																																																							1,380,620		1,380,620
Net income (loss)																																																																																																								1,465,104	1,465,104
Shares issued pursuant to note conversions																																																																																																						$ 3,987	144,584		148,571
Shares issued pursuant to note conversions (in shares)																																																																																																						398,734
Issuance of warrants																					$ 23,550		$ 23,550							$ 6,261,591		$ 6,261,591			$ 117,241		$ 117,241
Stock issued for Helomics acquisition																																																																																																					35,000	$ 40,000	5,537,250		5,612,250
Stock issued for Helomics acquisition (in shares)																																																																																																			3,500,000			4,000,000
Value of shares to extinguish debt																																																																																																						$ 86,373	6,376,936		6,463,309
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)																																																																																																						8,637,323
Issuance of Series E Preferred shares																																																																																																					1		743,559		743,560
Issuance of Series E Preferred shares (in shares)																																																																																																				84
Balance at Jun. 30, 2019																																																																																																					$ 35,793	$ 309,747	$ 86,882,073	$ (64,936,025)	$ 22,291,588
Balance (in shares) at Jun. 30, 2019																																																																																																		79,246	3,500,000	84		30,974,761

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flow from operating activities:
Net loss	$ (1,828,080)	$ (4,133,432)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable	795,353
Accrued interest revenue	(42,746)
Loss on equity method investment	439,637	960,508
Gain on revaluation of equity method investment	(6,164,260)
Depreciation and amortization	259,362	41,062
Vesting expense for stock options	1,644,220	460,368
Amortization of debt discount	1,068,256
Loss on valuation of equity-linked instruments	231,348
Gain on revaluation of cash advances to Helomics	(1,222,244)
Changes in assets and liabilities:
Accounts receivable	141,325	(177,828)
Inventories	(55,665)	20,385
Prepaid expense and other assets	66,989	14,490
Accounts payable	718,483	25,126
Accrued expenses	(104,114)	(329,889)
Deferred revenue	6,641	11,679
Net cash used in operating activities	(4,045,495)	(3,107,531)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advance on notes receivable	(975,000)	(42,524)
Cash received from notes receivable	154,418
Cash received in Helomics Acquisition	248,102
Purchase of fixed assets		(129,990)
Acquisition of intangibles	(8,433)	(27,524)
Net cash (used in) provided by investing activities:	(580,913)	44,933
Cash flow from financing activities:
Extinguishment of convertible debt	(220,241)
Proceeds from debt issuance	1,525,000
Proceeds from exercise of warrants into common stock	5,786	341,169
Proceeds from issuance of Series E convertible preferred stock	743,560
Issuance of common stock	2,479,708	2,959,509
Net cash provided by financing activities	4,533,813	3,300,678
Net decrease in cash and cash equivalents	(92,595)	238,080
Cash at beginning of period	162,152	766,189
Cash at end of period	69,557	1,004,269
Non-cash transactions:
Bridge loan conversion into common stock	238,573
Forbearance settlement bridge loan	503,009
Value of warrants issued	32,215
Consideration given for acquisition of Helomics	26,711,791	1,542,250
Conversion of preferred stock to common stock		$ 6,479

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 10, 2019. June 13, 2019. As of June 30, 2019, 30,974,761 $.01 two 1 2 April 2009, 510 On April 4, 2019, 2 149,000 first 2018, The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $64,936,025. not no may The Company had cash and cash equivalents of $69,557 June 30, 2019 one not may may 3, $2,100,000 2019. $4,300,000 June 2019, $776,000 June 30, 2019 $1,238,800 $3,500,000 In the quarter ended June 30, 2019, $776,000 $275,000 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2019. may not Recent Accounting Developments Accounting Policies and Estimates The presentation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. January 1, 2019, $353,007 $79,252 2016 02 not The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not See Note 8 Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the net realizable value, with cost determined on a first first June 30, December 31, Finished goods $ 150,340 $ 58,701 Raw materials 91,437 127,003 Work-In-Process 79,099 55,362 Total $ 320,876 $ 241,066 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 2 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4 The Company’s fixed assets consist of the following: June 30, December 31, Computers and office equipment $ 505,728 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 77,973 85,246 Laboratory equipment 1,401,210 - Total 2,281,880 539,218 Less: Accumulated depreciation 512,067 358,765 Total Fixed Assets, Net $ 1,769,813 $ 180,453 The large fluctuation in fixed assets is due to the Helomics acquisition (see Note 2 Depreciation expense was $131,420 $153,302 three six June 30, 2019 $18,825 $33,321 three six June 30, 2018. Intangible Assets Intangible assets consist of trademarks, patent costs, license fees, customer relationships and developed technology. Amortization expense was $88,416 $106,060 three six June 30, 2019 $4,070 $7,741 three six June 30, 2018. The Company reviews identifiable intangible assets for impairment in accordance with ASC 360 Property, Plant and Equipment may not not may not not 2 The components of intangible assets all of which except tradenames are finite-lived were as follows: 6/30/2019 12/31/2018 Gross Carrying Accumulated Net Gross Carrying Accumulated Net Patents & Trademarks $ 326,740 $ (188,698 ) $ 138,042 $ 318,303 $ (182,558 ) $ 135,745 Licensing Fees 877,500 (78,000 ) 799,500 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (34,823 ) 2,847,177 - - - Customer Relationships 445,000 (35,847 ) 409,153 - - - Tradename 398,000 - 398,000 - - - Total $ 4,929,240 $ (337,368 ) $ 4,591,872 $ 1,195,803 $ (231,308 ) $ 964,495 The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2019 Year ending Expense 2019 181,748 2020 363,497 2021 363,497 2022 264,609 2023 215,165 Thereafter 3,203,356 Total 4,591,872 Goodwill In accordance with ASC - 350, Intangibles – Goodwill and Other, not not may first not may first not 2018 no 2019 second 2019. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382 may not not 382 may 382 2020. Tax years subsequent to 2015 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no Segments The Company has five three six June 30, 2019 2 2018 Three Months Ended June 30, Six Months Ended June 30, 2019 2019 Domestic International Corporate/ Total Domestic International Corporate/ Total Revenue $ 259,082 $ 1,464 $ 25,605 $ 286,151 $ 478,743 $ 37,044 $ 25,605 $ 541,392 Segment Gain/(Loss) $ (917,754 ) $ (97,552 ) $ 2,480,410 $ 1,465,104 $ (1,859,477 ) $ (196,213 ) $ 227,610 $ (1,828,080 ) Net Assets as of, June 30, 2019 December 31, 2018 Domestic International Corporate/ Total Domestic International Corporate/ Total Net Assets $ 741,497 $ 34,841 $ 21,515,250 $ 22,291,588 $ 628,451 $ 41,377 $ (616,356 ) $ 53,472 Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not

Note 2 - Helomics Acquisition

Note 2 - Helomics Acquisition	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 2 The Company acquired 25% first 2018. April 4, 2019, ( 75% Helomics’ precision medicine services are designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy. Helomics’ precision oncology services are based on its D-CHIP diagnostic platform, which combines a database of genomic and drug response profiles from over 149,000 The acquisition of Helomics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the date of this filing. The Company incurred $656,615 The fair value of the consideration transferred in the acquisition has five $26,711,791. Value of shares to Helomics shareholders $ 5,612,250 Value of Helomics notes receivable forgiven 2,210,381 Value of shares to extinguish debt 6,463,309 Value of warrants issued 6,261,591 Gain on revaluation of equity method investment 6,164,260 Fair value of the consideration $ 26,711,791 Less assets acquired: Cash & cash equivalents 248,102 Accounts receivable 207,769 Inventory 17,727 Prepaid expenses 15,321 Fix assets, net 1,749,080 Intangible assets 3,725,000 Lease right of use assets 780,594 Plus liabilities assumed: Accounts payable 2,374,596 Note Payable 303,333 Accrued expenses 363,569 Lease Liability – Net of Long-term Portion 422,126 Lease liability 358,468 Total assets acquired and liabilities assumed (2,921,501 ) Goodwill $ 23,790,290 (i) Upon the acquisition, all outstanding shares of Helomics stock not 4,000,000 3,500,000 $5,612,250; $2,210,381; 8,637,323 $6,463,309; 14,245,063 23,741,772 597,000 $6,261,591; 25% 2018 $6,164,260 75% 10% The fair values of all common and preferred shares issued as consideration in the transaction was determined using the closing bid price of the Company’s common stock on April 4, 2019. The Company did not three not $303,333 90 583,003 $1.00 Identifiable Intangible Assets The Company acquired intangible assets related to trademarks for the acquired Helomics trade name with an estimated fair market value of $398,000. The Company acquired intangible assets with a useful life of three $445,000 The Company acquired intangible assets with a useful life of 20 $2,882,000 The acquisition costs related to the intangible assets are represented in legal and accounting expenses within general and administrative expenses in the statement of net loss. Goodwill The $23,790,290 None three Financial Results The financial results of Helomics since the acquisition date have been included in the Company’s unaudited condensed consolidated statements of net loss for the quarter. Pro Forma The following pro forma information presents the combined results of operations of Predictive and Helomics as if the acquisition of Helomics had been completed on January 1, 2018, Three Months Ended June 30, 2019 Revenue $ 286,376 Net gain attributable to Predictive $ 1,399,809 Six Months Ended June 30, 2019 Revenue $ 587,452 Net loss attributable to Predictive $ 3,240,611 The primary adjustments include the deduction of the original depreciation and amortization and the inclusion of the revalued depreciation and amortization for Helomics tangible and intangible assets. The unaudited pro forma results do not may not There are certain portions of purchase accounting, specifically Section 382 Tax Loss Carryforwards not may

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Revenue from Clinical Testing The Precision Oncology Insights are clinic diagnostic testing comprised of the Company’s ChemoFx and BioSpeciFx tests. The ChemoFx test determines how a tumor specimen reacts to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the expression of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are now generally considered implicit price concessions that are a reduction in revenue. Helomics payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one 1 For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue for these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation on the basis of the standalone selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 1 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of June 30, 2019, December 31, 2018, $299,046 $232,602, The Company deferred revenues related primarily to maintenance plans and CRO revenue of $29,706 $23,065 June 30, 2019 December 31, 2018, Practical Expedients The Company has elected the practical expedient not

Note 4 - Stockholders' Equity,

Note 4 - Stockholders' Equity, Stock Options and Warrants	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 Series D Preferred Shares The Company issued 3.5 1:1 50% one April 4, 2020. Series E Convertible Preferred Stock In June 2019, $843,000 350 $107,935, six June 30, 2019, Each Preferred Share Holder shall have the right at the Company’s option to be converted into 0.056857% six 12 Net Loss Attributable to common shareholders The net loss attributable to common shareholders for the six three June 30, 2019, $843,000 June 2019 $20,398, not not June 30, 2019 December 12, 2019 not 7 Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. For grants of stock option and warrants issued during the quarter ended June 30, 2019, 1.93% 2.55% 0% 78.6% 5 10 $0.3044 $.6060 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 1,098,858 1.01 2,336,154 1.07 Expired (194,564 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at December 31, 2018 3,669,277 $ 1.70 3,626,643 $ 4.17 Issued 3,731,868 0.72 17,212,545 0.95 Expired (101,397 ) 2.00 (919 ) 603.89 Exercised - - (578,560 ) 0.01 Outstanding at June 30, 2019 7,299,748 $ 1.20 20,259,709 $ 1.67 Stock-based compensation recognized for the three six June 30, 2019 $1,380,620 $1,644,220, three six June 30, 2018 $233,981 $460,368, $723,870 16 On April 4, 2019, 1,908,500 $0.01, April 4, 2019, 1,050,004 $0.01,

Note 5 - Notes Receivable

Note 5 - Notes Receivable	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 The Company has a secured promissory note receivable from CytoBioscience for $1,112,524, 8% February 28, 2020. 2019, first April 2019. not first $1,290,000. $250,000 As of April 3, 2019, $2,140,013, $70,369 2

Note 6 - Convertible Debt and D

Note 6 - Convertible Debt and Derivative Liability	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 Effective September 28, 2018, two $2,297,727 The bridge loan accrues interest at a rate of 8% twelve September 28, 2019. $1.00 70% 20 may 2,678,328 Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using 70% 20 $231,348 six June 30, 2019. June 30, 2019 $504,092. In the second one $148,573 398,734 $325,278. The value of the embedded derivative from the bridge loan as well as the derivative included in the note payable agreements with the Company’s CEO (See Note 9 3 1. six June 30, 2019. Derivative Liability Derivative Loss Recognized to Adjustments to Derivative Liability $ 272,745 69,722 231,347 32,215 $ 541,599

Note 7 - Loss Per Share

Note 7 - Loss Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 7 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended Six Months Ended 2019 2018 2019 2018 Numerator Net gain/(loss) attributable to common shareholder per common share basic and diluted calculation $ 1,444,706 $ (2,373,410 ) $ (1,848,478 ) $ (4,133,432 ) Net gain/(loss) 1,444,706 (2,373,410 ) (1,848,478 ) (4,133,432 ) Denominator: Weighted average common shares outstanding-basic 29,609,373 11,878,490 22,747,544 11,632,221 Effect of diluted stock options, warrants and preferred stock (1) 30,461,410 - - - Weighted average common shares outstanding-diluted 60,070,783 11,878,490 22,747,544 11,632,221 Gain/(Loss) per common share - basic $ 0.05 $ (0.20 ) $ (0.08 ) $ (0.36 ) Gain/(loss) per common share - diluted $ 0.02 $ (0.20 ) $ (0.08 ) $ (0.36 ) ( 1 June 30, 2019 June 30, 2018 27,559,457 5,676,637, June 30, 2019 June 30, 2018 1,303,073 June 30, 2019 June 30, 2018 79,246. June 30, 2019 June 30, 2018 35,000 June 30, 2019 June 30, 2018 1,484,634

Note 8 - Leases

Note 8 - Leases	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 8 The Company’s corporate offices are located at 2915 900, 55121. November 22, 2017, second January 28, 2013. three February 1, 2018 January 31, 2021. 5,773 2,945 2,828 Skyline Medical Europe’s offices are located at 9 1380 April 24, 2018 June 15, 2018. 2,000 750 1,250 June 14, 2027. Helomics’ offices are located at 91 43 rd October 17, 2017, second February 28, 2016. three February 1, 2018, January 31, 2021. 17,417 1,000 16,417 Lease expense was $153,923 $183,135 three six June 30, 2019 $19,936 $37,179 three six June 30, 2018, The following table summarizes other information related to the Company’s operating leases: June 30, 2019 Weighted average remaining lease term – operating leases in years 3.19 Weighted average discount rate – operating leases 8 % The Company’s rent obligation for the next five 2019 $ 259,700 2020 520,981 2021 118,976 2022 43,403 2023 44,271 2024 and thereafter 157,932 Total lease payments 1,145,263 Less interest 139,738 Present value of lease liabilities $ 1,005,525

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no On May 1, 2019, one three $13,500 On May 21, 2019, third second $1,620,000. 34,518 second $32,215. June 30, 2019, $36,507. May 9, 2019, $75,000 May 30, 2019, $200,000 July 15, 2019 $25,000 8% September 13, 2019, not not

Note 10 - Subsequent Events

Note 10 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 Related Party Transactions On July 15, 2019, $25,000 two May 2019 June 2019. three 8% September 13, 2019. Private Placement Funding On June 13, 2019, 4 $776,000 $1,238,800 $3,500,000 Skyline Restructuring In July 2019, ten $300,673. $247,500, one 24 twelve The Company continues to operate, both selling and maintaining, the STREAMWAY System and its disposable cleaning solution and bi-furcated filters.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. June 10, 2019, June 10, 2019. June 13, 2019. As of June 30, 2019, 30,974,761 $.01 two 1 2 April 2009, 510 On April 4, 2019, 2 149,000 first 2018, The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $64,936,025. not no may The Company had cash and cash equivalents of $69,557 June 30, 2019 one not may may 3, $2,100,000 2019. $4,300,000 June 2019, $776,000 June 30, 2019 $1,238,800 $3,500,000 In the quarter ended June 30, 2019, $776,000 $275,000
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2019. may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments Accounting Policies and Estimates The presentation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. January 1, 2019, $353,007 $79,252 2016 02 not The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not See Note 8
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the net realizable value, with cost determined on a first first June 30, December 31, Finished goods $ 150,340 $ 58,701 Raw materials 91,437 127,003 Work-In-Process 79,099 55,362 Total $ 320,876 $ 241,066
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 2 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4 The Company’s fixed assets consist of the following: June 30, December 31, Computers and office equipment $ 505,728 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 77,973 85,246 Laboratory equipment 1,401,210 - Total 2,281,880 539,218 Less: Accumulated depreciation 512,067 358,765 Total Fixed Assets, Net $ 1,769,813 $ 180,453 The large fluctuation in fixed assets is due to the Helomics acquisition (see Note 2 Depreciation expense was $131,420 $153,302 three six June 30, 2019 $18,825 $33,321 three six June 30, 2018.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks, patent costs, license fees, customer relationships and developed technology. Amortization expense was $88,416 $106,060 three six June 30, 2019 $4,070 $7,741 three six June 30, 2018. The Company reviews identifiable intangible assets for impairment in accordance with ASC 360 Property, Plant and Equipment may not not may not not 2 The components of intangible assets all of which except tradenames are finite-lived were as follows: 6/30/2019 12/31/2018 Gross Carrying Accumulated Net Gross Carrying Accumulated Net Patents & Trademarks $ 326,740 $ (188,698 ) $ 138,042 $ 318,303 $ (182,558 ) $ 135,745 Licensing Fees 877,500 (78,000 ) 799,500 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (34,823 ) 2,847,177 - - - Customer Relationships 445,000 (35,847 ) 409,153 - - - Tradename 398,000 - 398,000 - - - Total $ 4,929,240 $ (337,368 ) $ 4,591,872 $ 1,195,803 $ (231,308 ) $ 964,495 The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2019 Year ending Expense 2019 181,748 2020 363,497 2021 363,497 2022 264,609 2023 215,165 Thereafter 3,203,356 Total 4,591,872
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC - 350, Intangibles – Goodwill and Other, not not may first not may first not 2018 no 2019 second 2019.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382 may not not 382 may 382 2020. Tax years subsequent to 2015
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one no
Segment Reporting, Policy [Policy Text Block]	Segments The Company has five operating segments: domestic sales, international sales, diagnostic revenue, CRO revenue and clinical testing revenue. The revenues earned in diagnostic, CRO and clinical testing are immaterial to the total revenues earned and are currently represented in Other Revenue in the table below. The segment revenues and net losses for the three-month and six-month periods ended June 30, 2019 are described in the table below. There are significant changes in the Company’s assets relating to the Helomics acquisition specifically in the other segment for intangibles, tangible fixed assets and goodwill (see Note 2). In 2018 substantially all the Company assets, revenues and expenses were located or derived from operations in the United States and recorded under the Domestic Revenue segment. Three Months Ended June 30, Six Months Ended June 30, 2019 2019 Domestic International Corporate/ Total Domestic International Corporate/ Total Revenue $ 259,082 $ 1,464 $ 25,605 $ 286,151 $ 478,743 $ 37,044 $ 25,605 $ 541,392 Segment Gain/(Loss) $ (917,754 ) $ (97,552 ) $ 2,480,410 $ 1,465,104 $ (1,859,477 ) $ (196,213 ) $ 227,610 $ (1,828,080 ) Net Assets as of, June 30, 2019 December 31, 2018 Domestic International Corporate/ Total Domestic International Corporate/ Total Net Assets $ 741,497 $ 34,841 $ 21,515,250 $ 22,291,588 $ 628,451 $ 41,377 $ (616,356 ) $ 53,472
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, Finished goods $ 150,340 $ 58,701 Raw materials 91,437 127,003 Work-In-Process 79,099 55,362 Total $ 320,876 $ 241,066
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 2 Manufacturing tooling 3 - 7 Demo equipment 3 Laboratory equipment 4
Property, Plant and Equipment [Table Text Block]	June 30, December 31, Computers and office equipment $ 505,728 $ 204,903 Leasehold improvements 188,014 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 77,973 85,246 Laboratory equipment 1,401,210 - Total 2,281,880 539,218 Less: Accumulated depreciation 512,067 358,765 Total Fixed Assets, Net $ 1,769,813 $ 180,453
Schedule of Finite-Lived Intangible Assets [Table Text Block]	6/30/2019 12/31/2018 Gross Carrying Accumulated Net Gross Carrying Accumulated Net Patents & Trademarks $ 326,740 $ (188,698 ) $ 138,042 $ 318,303 $ (182,558 ) $ 135,745 Licensing Fees 877,500 (78,000 ) 799,500 877,500 (48,750 ) 828,750 Developed Technology 2,882,000 (34,823 ) 2,847,177 - - - Customer Relationships 445,000 (35,847 ) 409,153 - - - Tradename 398,000 - 398,000 - - - Total $ 4,929,240 $ (337,368 ) $ 4,591,872 $ 1,195,803 $ (231,308 ) $ 964,495
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending Expense 2019 181,748 2020 363,497 2021 363,497 2022 264,609 2023 215,165 Thereafter 3,203,356 Total 4,591,872
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2019 2019 Domestic International Corporate/ Total Domestic International Corporate/ Total Revenue $ 259,082 $ 1,464 $ 25,605 $ 286,151 $ 478,743 $ 37,044 $ 25,605 $ 541,392 Segment Gain/(Loss) $ (917,754 ) $ (97,552 ) $ 2,480,410 $ 1,465,104 $ (1,859,477 ) $ (196,213 ) $ 227,610 $ (1,828,080 ) Net Assets as of, June 30, 2019 December 31, 2018 Domestic International Corporate/ Total Domestic International Corporate/ Total Net Assets $ 741,497 $ 34,841 $ 21,515,250 $ 22,291,588 $ 628,451 $ 41,377 $ (616,356 ) $ 53,472

Note 2 - Helomics Acquisition (

Note 2 - Helomics Acquisition (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Value of shares to Helomics shareholders $ 5,612,250 Value of Helomics notes receivable forgiven 2,210,381 Value of shares to extinguish debt 6,463,309 Value of warrants issued 6,261,591 Gain on revaluation of equity method investment 6,164,260 Fair value of the consideration $ 26,711,791 Less assets acquired: Cash & cash equivalents 248,102 Accounts receivable 207,769 Inventory 17,727 Prepaid expenses 15,321 Fix assets, net 1,749,080 Intangible assets 3,725,000 Lease right of use assets 780,594 Plus liabilities assumed: Accounts payable 2,374,596 Note Payable 303,333 Accrued expenses 363,569 Lease Liability – Net of Long-term Portion 422,126 Lease liability 358,468 Total assets acquired and liabilities assumed (2,921,501 ) Goodwill $ 23,790,290
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended June 30, 2019 Revenue $ 286,376 Net gain attributable to Predictive $ 1,399,809 Six Months Ended June 30, 2019 Revenue $ 587,452 Net loss attributable to Predictive $ 3,240,611

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 1,098,858 1.01 2,336,154 1.07 Expired (194,564 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at December 31, 2018 3,669,277 $ 1.70 3,626,643 $ 4.17 Issued 3,731,868 0.72 17,212,545 0.95 Expired (101,397 ) 2.00 (919 ) 603.89 Exercised - - (578,560 ) 0.01 Outstanding at June 30, 2019 7,299,748 $ 1.20 20,259,709 $ 1.67

Note 6 - Convertible Debt and_2

Note 6 - Convertible Debt and Derivative Liability (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative Liability Derivative Loss Recognized to Adjustments to Derivative Liability $ 272,745 69,722 231,347 32,215 $ 541,599

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended 2019 2018 2019 2018 Numerator Net gain/(loss) attributable to common shareholder per common share basic and diluted calculation $ 1,444,706 $ (2,373,410 ) $ (1,848,478 ) $ (4,133,432 ) Net gain/(loss) 1,444,706 (2,373,410 ) (1,848,478 ) (4,133,432 ) Denominator: Weighted average common shares outstanding-basic 29,609,373 11,878,490 22,747,544 11,632,221 Effect of diluted stock options, warrants and preferred stock (1) 30,461,410 - - - Weighted average common shares outstanding-diluted 60,070,783 11,878,490 22,747,544 11,632,221 Gain/(Loss) per common share - basic $ 0.05 $ (0.20 ) $ (0.08 ) $ (0.36 ) Gain/(loss) per common share - diluted $ 0.02 $ (0.20 ) $ (0.08 ) $ (0.36 )

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	June 30, 2019 Weighted average remaining lease term – operating leases in years 3.19 Weighted average discount rate – operating leases 8 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2019 $ 259,700 2020 520,981 2021 118,976 2022 43,403 2023 44,271 2024 and thereafter 157,932 Total lease payments 1,145,263 Less interest 139,738 Present value of lease liabilities $ 1,005,525

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual)	1 Months Ended			3 Months Ended		6 Months Ended
	Aug. 13, 2019USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Apr. 04, 2019$ / shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares
Common Stock, Shares, Outstanding, Ending Balance | shares		30,974,761		30,974,761		30,974,761				14,091,748
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01		$ 0.01		$ 0.01		$ 0.01		$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance		$ (64,936,025)		$ (64,936,025)		$ (64,936,025)				$ (63,107,945)
Cash and Cash Equivalents, at Carrying Value, Ending Balance		69,557		69,557		69,557				162,152
Operating Lease, Right-of-Use Asset		1,005,525		1,005,525		1,005,525
Operating Lease, Liability, Current		501,427		501,427		501,427
Depreciation, Total				131,420	$ 18,825	153,302	$ 33,321
Amortization of Intangible Assets, Total				88,416	$ 4,070	106,060	$ 7,741
Income Tax Expense (Benefit), Total						0
Unrecognized Tax Benefits, Ending Balance		0		0		0
Liability for Uncertainty in Income Taxes, Current		0		0		$ 0
Open Tax Year						2015 2016 2017 2018
Number of Operating Segments						5
Operating Lease, Liability, Total		1,005,525		1,005,525		$ 1,005,525
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset									$ 353,007
Operating Lease, Liability, Current									79,252
Operating Lease, Liability, Total									$ 353,007
Convertible Promissory Note [Member]
Proceeds from Debt, Net of Issuance Costs			$ 275,000
S-3 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total						2,100,000
Issuance or Sale of Equity, Potentially Issuable		4,300,000		4,300,000		4,300,000
Private Placement [Member]
Proceeds from Issuance or Sale of Equity, Total		776,000
Issuance or Sale of Equity, Potentially Issuable		$ 3,500,000		$ 3,500,000		$ 3,500,000
Private Placement [Member] | Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 1,238,800

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Finished goods	$ 150,340	$ 58,701
Raw materials	91,437	127,003
Work-In-Process	79,099	55,362
Total	$ 320,876	$ 241,066

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	6 Months Ended
	Jun. 30, 2019
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	2 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significa_6

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Property, Plant, and Equipment Gross	$ 2,281,880	$ 539,218
Less: Accumulated depreciation	512,067	358,765
Total Fixed Assets, Net	1,769,813	180,453
Office Equipment [Member]
Property, Plant, and Equipment Gross	505,728	204,903
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	188,014	140,114
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	77,973	85,246
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	$ 1,401,210

Note 1 - Summary of Significa_7

Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Gross Carrying Costs	$ 4,929,240	$ 1,195,803
Accumulated Amortization	(337,368)	(231,308)
Net Carrying Amount	4,591,872	964,495
Patents and Trademarks [Member]
Gross Carrying Costs	326,740	318,303
Accumulated Amortization	(188,698)	(182,558)
Net Carrying Amount	138,042	135,745
Licensing Agreements [Member]
Gross Carrying Costs	877,500	877,500
Accumulated Amortization	(78,000)	(48,750)
Net Carrying Amount	799,500	828,750
Developed Technology Rights [Member]
Gross Carrying Costs	2,882,000
Accumulated Amortization	(34,823)
Net Carrying Amount	2,847,177
Customer Relationships [Member]
Gross Carrying Costs	445,000
Accumulated Amortization	(35,847)
Net Carrying Amount	409,153
Trade Names [Member]
Gross Carrying Costs	398,000
Accumulated Amortization
Net Carrying Amount	$ 398,000

Note 1 - Summary of Significa_8

Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
2019	$ 181,748
2020	363,497
2021	363,497
2022	264,609
2023	215,165
Thereafter	3,203,356
Total	$ 4,591,872	$ 964,495

Note 1 - Summary of Significa_9

Note 1 - Summary of Significant Accounting Policies - Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Revenue	$ 286,151	$ 358,586	$ 541,392	$ 770,179
Segment Gain/(Loss)	1,465,104	$ (2,373,410)	(1,828,080)	$ (4,133,432)
Net Assets	22,291,588		22,291,588		$ 53,472
Domestic [Member]
Revenue	259,082		478,743
Segment Gain/(Loss)	(917,754)		(1,859,477)
Net Assets	741,497		741,497		628,451
International [Member]
Revenue	1,464		37,044
Segment Gain/(Loss)	(97,552)		(196,213)
Net Assets	34,841		34,841		41,377
Other Segments [Member]
Revenue	25,605		25,605
Segment Gain/(Loss)	2,480,410		227,610
Net Assets	$ 21,515,250		$ 21,515,250		$ (616,356)

Note 2 - Helomics Acquisition_2

Note 2 - Helomics Acquisition (Details Textual) - USD ($)	Apr. 04, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Mar. 31, 2018
Stock Issued During Period, Value, Extinguishment of Debt		$ 6,463,309	$ 6,463,309
Warrants Issued			32,215
Goodwill, Ending Balance		$ 23,790,290	$ 23,790,290
Notes Issued to Helomics' Noteholders [Member]
Debt Instrument, Term	90 years
Debt Instrument, Face Amount	$ 303,333
Warrants Held by Noteholders [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	583,003
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage						25.00%
Business Acquisition, Percentage of Voting Interests Acquired	75.00%
Business Combination, Acquisition Related Costs	$ 656,615
Business Combination, Consideration Transferred, Total	26,711,791
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	5,612,250
Business Combination, Notes and Interest Due Forgave	$ 2,210,381
Stock Issued During Period, Shares, Extinguishment of Debt	8,637,323
Stock Issued During Period, Value, Extinguishment of Debt	$ 6,463,309
Warrants Issued	6,261,591
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	6,164,260
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	3,725,000
Goodwill, Ending Balance	23,790,290
Helomics Holding Corp. [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	398,000
Helomics Holding Corp. [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 445,000
Finite-Lived Intangible Asset, Useful Life	3 years
Helomics Holding Corp. [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 2,882,000
Finite-Lived Intangible Asset, Useful Life	20 years
Helomics Holding Corp. [Member] | Warrants Issued to Holders of Helomics Notes and Warrants [Member]
Class of Warrant or Right Issued During Period	14,245,063
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	23,741,772
Helomics Holding Corp. [Member] | Warrants Held by Other Parties [Member]
Class of Warrant or Right Issued During Period	597,000
Helomics Holding Corp. [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	4,000,000
Helomics Holding Corp. [Member] | Series D Convertible Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,500,000

Note 2 - Helomics Acquisition -

Note 2 - Helomics Acquisition - Fair value of Assets and Liabilities Assumed (Details) - USD ($)	Apr. 04, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Value of shares to extinguish debt		$ 6,463,309	$ 6,463,309
Value of warrants issued			32,215
Goodwill, Ending Balance		$ 23,790,290	$ 23,790,290
Helomics Holding Corp. [Member]
Value of shares to Helomics shareholders	$ 5,612,250
Value of Helomics notes receivable forgiven	2,210,381
Value of shares to extinguish debt	6,463,309
Value of warrants issued	6,261,591
Business Acquisition, Revaluation, Gain (Loss) on Acquisition	6,164,260
Fair value of the consideration	26,711,791
Cash & cash equivalents	248,102
Accounts receivable	207,769
Inventory	17,727
Prepaid expenses	15,321
Fix assets, net	1,749,080
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	3,725,000
Lease right of use assets	780,594
Accounts payable	2,374,596
Note Payable	303,333
Accrued expenses	363,569
Lease Liability – Net of Long-term Portion	422,126
Lease liability	358,468
Total assets acquired and liabilities assumed	(2,921,501)
Goodwill, Ending Balance	$ 23,790,290

Note 2 - Helomics Acquisition_3

Note 2 - Helomics Acquisition - Pro Forma Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Revenue	$ 286,376	$ 587,452
Net gain attributable to Predictive	$ 1,399,809	$ 3,240,611

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 299,046	$ 232,602
Contract with Customer, Liability, Current	$ 29,706	$ 23,065
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual) - USD ($)	Apr. 04, 2019	Jun. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Jun. 13, 2019
Stock Issued During Period, Value, New Issues							$ 2,755,087
Temporary Equity, Dividends, Adjustment			$ 20,398			$ 20,398
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			78.60%
Share-based Payment Arrangement, Expense			$ 1,380,620		$ 233,981	1,644,220	$ 460,368
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 723,870	$ 723,870			$ 723,870
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01			$ 0.01		$ 0.01
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value						$ 0.72		$ 1.01
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition						1 year 120 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						3,731,868		1,098,858
Stock Options Issued to Predictive [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,908,500
Stock Options Issued with Helomics Acquisition [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,050,004
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			2.55%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 0.606
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.93%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 0.3044
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						3 years
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total	3,500,000
Convertible Preferred Stock, Conversion Rate	1.00%
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate		0.05686%
Stock Issued During Period, Value, New Issues		$ 843,000
Preferred Stock, Shares Authorized		350	350			350
Preferred Stock, Beneficial Conversion Feature		$ 107,935	$ 107,935			$ 107,935
Temporary Equity, Dividends, Adjustment		$ 20,398
Temporary Equity, Liquidation Preference									$ 0

Note 4 - Stockholders' Equity_4

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Warrant [Member]
Number of Shares Outstanding (in shares)	3,626,643	1,951,257
Average Exercise Price Outstanding (in dollars per share)	$ 4.17	$ 23.74
Number of Shares Issued (in shares)	17,212,545	2,336,154
Average Exercise Price Issued (in dollars per share)	$ 0.95	$ 1.07
Number of Shares Expired (in shares)	(919)	(10,706)
Average Exercise Price Expired (in dollars per share)	$ 603.89	$ 199.55
Number of Shares Exercised (in shares)	(578,560)	(650,062)
Average Exercise Price Exercised (in dollars per share)	$ 0.01	$ 1
Number of Shares Outstanding (in shares)	20,259,709	3,626,643
Average Exercise Price Outstanding (in dollars per share)	$ 1.67	$ 4.17
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	3,669,277	2,764,983
Average Exercise Price Outstanding (in dollars per share)	$ 1.70	$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,731,868	1,098,858
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.72	$ 1.01
Number of Shares Expired (in shares)	(101,397)	(194,564)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 2
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	7,299,748	3,669,277
Average Exercise Price Outstanding (in dollars per share)	$ 1.20	$ 1.70

Note 5 - Notes Receivable (Deta

Note 5 - Notes Receivable (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2019	Apr. 03, 2019
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total	$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage	8.00%
Proceeds from Collection of Notes Receivable	$ 0
Note Receivable, Collateral Value	1,290,000
Note Receivable Collateral Fair Value	$ 250,000
Helomics Holding Corp. [Member]
Financing Receivable, before Allowance for Credit Loss, Total		$ 2,140,013
Interest Receivable		$ 70,369

Note 6 - Convertible Debt and_3

Note 6 - Convertible Debt and Derivative Liability (Details Textual) - USD ($)	Sep. 28, 2018	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Derivative Liability, Total		$ 541,599	$ 541,599		$ 272,745
Debt Conversion, Converted Instrument, Amount			238,573
Embedded Derivative Financial Instruments [Member]
Unrealized Gain (Loss) on Derivatives			(231,348)
Derivative Liability, Total		504,092	504,092
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount	$ 2,297,727
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Term	1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock	70.00%
Debt Instrument, Convertible, Threshold Trading Days	20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares	2,678,328
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price	$ 1
Bridge Notes [Member]
Debt Conversion, Original Debt, Amount		148,573
Debt Conversion, Converted Instrument, Amount		398,734
Convertible Debt, Total		$ 325,278	$ 325,278

Note 6 - Convertible Debt and_4

Note 6 - Convertible Debt and Derivative Liability - Change in Fair Value of Derivative Liabilities (Details)	6 Months Ended
	Jun. 30, 2019USD ($)
Derivative liability	$ 272,745
Derivative instrument issued	69,722
Loss recognized to revalue derivative instrument at fair value	231,347
Adjustments to derivative liability for warrants issued	32,215
Derivative liability	$ 541,599

Note 7 - Loss Per Share (Detail

Note 7 - Loss Per Share (Details Textual) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	27,559,457	5,676,637
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,303,073
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246	79,246
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	35,000	0
Series E Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,484,634	0

Note 7 - Loss Per Share - Share

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net gain/(loss) attributable to common shareholder per common share basic and diluted calculation		$ 1,444,706	$ (2,373,410)	$ (1,848,478)	$ (4,133,432)
Net gain/(loss)		$ 1,444,706	$ (2,373,410)	$ (1,848,478)	$ (4,133,432)
Weighted average shares used in computation - basic (in shares)		29,609,373	11,878,490	22,747,544	11,632,221
Effect of diluted stock options, warrants and preferred stock (1) (in shares)	[1]	30,461,410
Weighted average common shares outstanding-diluted (in shares)		60,070,783	11,878,490	22,747,544	11,632,221
Gain/(loss) per common share - basic (in dollars per share)		$ 0.05	$ (0.20)	$ (0.08)	$ (0.36)
Gain/(loss) per common share – diluted (in dollars per share)		$ 0.02	$ (0.20)	$ (0.08)	$ (0.36)
[1]	The number of shares underlying options and warrants outstanding as of June 30, 2019 and June 30, 2018 are 27,559,457 and 5,676,637, respectively. The number of shares underlying the convertible debt as of June 30, 2019 and June 30, 2018 is 1,303,073 and zero, respectively. The number of shares underlying the preferred stock Series C as of June 30, 2019 and June 30, 2018 is 79,246. The number of shares underlying the preferred stock Series D as of June 30, 2019 and June 30, 2018 is 35,000 and zero, respectively. The number of shares underlying the preferred stock Series E as of June 30, 2019 and June 30, 2018 is 1,484,634 and zero, respectively. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 15, 2018ft²	Feb. 01, 2018ft²	Oct. 17, 2017ft²
Operating Leases, Rent Expense, Total | $	$ 153,923	$ 19,936	$ 183,135	$ 37,179
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract						3 years
Area of Real Estate Property						5,773
Corporate Office, Minnesota [Member] | Office Space [Member]
Area of Real Estate Property						2,945
Corporate Office, Minnesota [Member] | Manufacturing Facility [Member]
Area of Real Estate Property						2,828
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property					2,000
Skyline Medical Europe’s Offices Lease [Member] | Office Space [Member]
Area of Real Estate Property					1,250
Skyline Medical Europe’s Offices Lease [Member] | Storage Space [Member]
Area of Real Estate Property					750
Helomics' Offices [Member]
Area of Real Estate Property							17,417
Helomics' Offices [Member] | Office Space [Member]
Area of Real Estate Property							1,000
Helomics' Offices [Member] | Laboratory [Member]
Area of Real Estate Property							16,417

Note 8 - Leases - Lease Informa

Note 8 - Leases - Lease Information (Details)	Jun. 30, 2019
Weighted average remaining lease term – operating leases in years (Year)	3 years 69 days
Weighted average discount rate – operating leases	8.00%

Note 8 - Leases - Rent Obligati

Note 8 - Leases - Rent Obligation (Details)	Jun. 30, 2019USD ($)
2019	$ 259,700
2020	520,981
2021	118,976
2022	43,403
2023	44,271
2024 and thereafter	157,932
Total lease payments	1,145,263
Less interest	139,738
Present value of lease liabilities	$ 1,005,525

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Details Textual) - USD ($)	Jul. 15, 2019	May 30, 2019	May 21, 2019	May 09, 2019	Oct. 31, 2018	Jun. 30, 2019	Dec. 31, 2018
Derivative Liability, Total						$ 541,599	$ 272,745
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total						$ 504,092
Director [Member]
Related Party Transaction, Monthly Cash Payment					$ 13,500
Chief Executive Officer [Member]
Proceeds from Related Party Debt			$ 1,620,000
Chief Executive Officer [Member] | Loans From Dr. Schwartz [Member]
Proceeds from Related Party Debt		$ 200,000		$ 75,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Chief Executive Officer [Member] | Loans From Dr. Schwartz [Member] | Subsequent Event [Member]
Proceeds from Related Party Debt	$ 25,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Chief Executive Officer [Member] | Schwartz Warrant [Member]
Class of Warrant or Right Issued During Period						34,518
Chief Executive Officer [Member] | Schwartz Warrant [Member] | Embedded Derivative Financial Instruments [Member]
Derivative Liability, Change in Fair Value Due to Issuance of Warrants						$ 32,215
Derivative Liability, Total						$ 36,507

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - USD ($)	Jul. 15, 2019	Jun. 13, 2019	May 30, 2019	May 21, 2019	May 09, 2019	Aug. 13, 2019	Jul. 31, 2019
Private Placement [Member] | Series E Convertible Preferred Stock [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs		$ 776,000
Chief Executive Officer [Member]
Proceeds from Related Party Debt				$ 1,620,000
Subsequent Event [Member] | Skyline Lay-offs [Member]
Severance Costs							$ 300,673
Subsequent Event [Member] | Skyline Lay-offs [Member] | One Individual [Member]
Severance Costs							$ 247,500
Subsequent Event [Member] | Private Placement [Member] | Series E Convertible Preferred Stock [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs						$ 1,238,800
Expected Gross Proceeds from Issuance of Equity						$ 3,500,000
Loans From Dr. Schwartz [Member] | Chief Executive Officer [Member]
Proceeds from Related Party Debt			$ 200,000		$ 75,000
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Loans From Dr. Schwartz [Member] | Subsequent Event [Member] | Chief Executive Officer [Member]
Proceeds from Related Party Debt	$ 25,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%